Research Journal of Pharmacy and Technology

Ahmed Abdullah Khan ¹, Hefazat Hussain Siddiqui ¹, Tarique Mahmood Ansari ¹, Farogh Ahsan ¹

Affiliations
1 Integral University, Lucknow-226026, (U.P), IN

Abstract

Citrus limetta risso (Rutaceae) has been frequently used in Indian traditional medicine for the treatment of hyperlipidemia and promotion of weight loss. Studies also indicated towards the antihyperlipidemic potential of Metformin. This study was performed on high fat diet (HFD) induced hyperlipidemia in murine models in both presence and absence of diabetes which was induced by dose of 30mg/kg. Hyperlipidemia was induced by feeding rats with HFD for 28 days. Antihyperlipidemic effect of Citrus limetta peel extract (400mg/kg) and its main terpene component D-limonene (400mg/kg) was evaluated and compared with the effect of Metformin (200mg/kg) by the measurement of body weight gain, body mass index(BMI), food efficiency ratio, fasting blood glucose, Lee’s index, heart to body weight ratio, serum lipid profiles (triglycerides, total cholesterol, HDL-Cholesterol, LDL-Cholesterol, VLDL-Cholesterol), end organ weights (Liver, heart, kidneys and visceral fat pad) and antioxidant enzymes such as Thiobarbituric acid (TBARS), Superoxide dismutase (SOD), Catalase (CAT) and Glutathione (GSH). Histomorphological studies were also carried out. Citrus limetta extract, D-limonene and Metformin significantly reduced the weight gain percentage, total cholesterol, LDL and VLDL and increased the level of HDL-cholesterol and antioxidant enzyme level in liver tissue, also controlled the other parameters’ value within their normal ranges. Histomorphological study of fat tissue shows the normalization of swollen and slight deteriorated cells in the treated groups as compared to control groups. This study concludes that Citrus limetta extract and D-limonene have the antihyperlipidemic activity.

Keywords

Hyperlipidemia, Consumption, Accumulation.

Full Text

     

Hema Jaiswal ¹, Vaseem Ahamad Ansari ¹, J. N. Pandit ¹, Farogh Ahsan ¹

Affiliations
1 Department of Pharmaceutics, Institute of Pharmaceutical Sciences and Research, Unnao (U.P.), IN

Abstract

In the current scenario of pharmaceutical research much attention has been focused on patients’ health in terms of therapeutic efficacy and safety so keeping this thing in mind, the objective of the study is to make an attempt to control the tradition of prescribing the doses of medication throughout a period of 24 hours as different researches have given the idea of administration of medications with day-night pattern and biological rhythms to reduce the dose frequency. Pulsatile drug delivery system is designed according to the circadian rhythm of the body, and the drug is released rapidly and completely as a pulse after a lag time. Products follow the sigmoid release profile characterized by a time period. This delivery system follow chronopharmacological behavior, where night-time dosing is required, and for drugs that show the first-pass effect. This review article was designed to throw light on marketed techniques of pulsatile drug delivery and to investigate the pulsatile release of Losantan and Captopril, based on chronotherapeutic consideration. The principle rationale for the use of pulsatile release of the drugs is where a constant drug release is not required and drug delivery should be such that there is complete drug release after a lag time. Lag time is defined as the time between when a dosage form is placed into an aqueous environment and the time at which the active ingredient begins to get released from the dosage form. This article focuses on the importance of pulsatile drug delivery system along with the study of different pulsatile release dosage forms containing Losartan (ARB-Angiotensin Receptor Blocker) and Captopril (ACE inhibitor-Angiotensin Converting Enzyme inhibitor).

Keywords

Pulsatile Release, Chronopharmacotherapy, Lags Time, Losartan, Captopril.

Full Text